[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"neuroprotection\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:neuroprotection":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,42,81,104],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":4},"100648039","phase-3-normobaric-hyperoxia-with-extended-window-endovascular-therapy-for-acute-ischemic-stroke-opens-extend-100648039",false,"NCT07717216","Normobaric Hyperoxia With Extended-Window Endovascular Therapy for Acute Ischemic Stroke (OPENS-EXTEND)","Efficacy and Safety of Periprocedural Normobaric Hyperoxia With Endovascular Therapy for Acute Ischemic Stroke 6-24 Hours After Last Known Well: A Multicenter Randomized Sham-Controlled Phase 3 Trial","Inclusion Criteria:\n\n1. Age 18 years or older.\n2. Clinical signs and symptoms consistent with acute anterior-circulation ischemic stroke, with a National Institutes of Health Stroke Scale (NIHSS) score of 10 or greater at the time of randomization.\n3. Pre-stroke modified Rankin Scale (mRS) score of 0 or 1.\n4. Alberta Stroke Program Early Computed Tomography Score (ASPECTS) of 6 or greater on baseline non-contrast computed tomography or diffusion-weighted magnetic resonance imaging.\n5. Eligible for endovascular therapy according to current guideline-recommended clinical practice and the judgment of the treating stroke team and neurointerventional team.\n6. Randomization can be completed between 6 and 24 hours after the time the participant was last known well. Randomization and initiation of the study intervention must not cause an avoidable delay in endovascular therapy.\n7. Pre-procedural computed tomography angiography or magnetic resonance angiography confirms large-vessel occlusion consistent with the participant's neurological deficits, involving one of the following: internal carotid artery or M1 segment of the middle cerebral artery.\n8. Baseline level of consciousness score on item 1a of the NIHSS is 0 or 1.\n9. Written informed consent has been obtained from the participant or the participant's legally authorized representative.\n\nExclusion Criteria:\n\n* General Exclusion Criteria\n\n  1. NIHSS score of less than 10 at the time of randomization; substantial neurological improvement such that the participant is no longer considered eligible for endovascular therapy; or imaging-confirmed spontaneous recanalization with no remaining treatable target-vessel occlusion.\n  2. Seizure at stroke onset when the current neurological deficits are considered primarily attributable to a postictal state, or when a reliable baseline NIHSS assessment cannot be obtained.\n  3. Active clinically significant bleeding or a bleeding diathesis that, in the judgment of the investigator or treating clinical team, makes endovascular therapy or participation in the study unsafe.\n  4. Platelet count below 100 × 10⁹\u002FL.\n  5. Clinically significant coagulation abnormality, anticoagulant exposure, or coagulation-factor deficiency that, according to the local standard of care at the participating center, makes the participant ineligible for endovascular therapy.\n  6. Severe or end-stage cardiac, hepatic, or renal dysfunction that is expected to substantially affect 90-day survival, functional outcome assessment, or the safety of study participation.\n  7. Persistent baseline blood glucose below 50 mg\u002FdL (2.78 mmol\u002FL) or above 400 mg\u002FdL (22.20 mmol\u002FL) after appropriate initial evaluation or correction.\n  8. Persistent systolic blood pressure above 185 mmHg or diastolic blood pressure above 110 mmHg despite appropriate antihypertensive treatment.\n  9. Life expectancy of less than 90 days because of a pre-existing disease or other underlying medical condition.\n  10. Known pregnancy.\n  11. Any of the following clinically significant respiratory diseases or conditions that, in the investigator's judgment, may make high-concentration oxygen therapy unsafe or interfere with reliable administration of the study intervention:chronic obstructive pulmonary disease; acute pulmonary infection; acute respiratory distress syndrome;clinically significant pleural effusion;chronic hypercapnic respiratory failure; another respiratory condition that may affect the safety of high-concentration oxygen therapy or the administration of the mask-based intervention.\n  12. Any of the following conditions before randomization: requirement for supplemental oxygen at a flow rate greater than 3 L\u002Fmin to maintain peripheral oxygen saturation above 94%;requirement for noninvasive ventilatory support because of respiratory failure; or requirement for invasive mechanical ventilation because of respiratory failure.\n  13. Persistent clinically significant vital-sign instability after initial treatment, including but not limited to: heart rate of 50 beats per minute or lower or 120 beats per minute or higher; peripheral oxygen saturation of 90% or lower;respiratory rate of 10 breaths per minute or lower or 30 breaths per minute or higher; or other unstable vital signs considered by the investigator to potentially compromise participant safety.\n  14. Active vomiting, a high risk of aspiration, or inability to tolerate the study mask, except for participants who require clinically indicated endotracheal intubation and mechanical ventilation.\n  15. Active gastrointestinal bleeding.\n  16. History of a severe adverse reaction to iodinated contrast media that cannot be adequately managed with premedication, an alternative contrast strategy, or other appropriate clinical measures and therefore precludes endovascular therapy.\n  17. Current participation in another interventional clinical trial that may interfere with the study intervention, safety assessment, or evaluation of study outcomes.\n  18. Any other disease, condition, or circumstance that, in the investigator's judgment, makes the participant unsuitable for the study or may interfere with study treatment, participant safety, or outcome assessment. The specific reason must be documented.\n* Imaging Exclusion Criteria\n\n  1. Evidence of intracranial hemorrhage on baseline computed tomography or magnetic resonance imaging, including but not limited to intraparenchymal hemorrhage, subarachnoid hemorrhage, subdural hemorrhage, or epidural hemorrhage.\n  2. Failure to meet the prespecified perfusion-mismatch imaging criteria, including an ischemic core volume of 70 mL or greater.\n  3. Pre-randomization computed tomography angiography or magnetic resonance angiography demonstrates abnormal vascular anatomy or excessive vascular tortuosity such that, in the judgment of the treating neurointerventionalist, the target vessel cannot be safely accessed with endovascular devices or endovascular therapy is technically infeasible.\n  4. Based on the medical history, computed tomography angiography, magnetic resonance angiography, or other imaging findings, any of the following is suspected to be the primary cause of the index stroke and is considered to make endovascular therapy inappropriate or unsafe: cerebral vasculitis; aortic dissection; cervical arterial dissection; or intracranial arterial dissection.\n  5. Intracranial vascular occlusions involving multiple independent vascular territories, bilateral anterior-circulation infarction, or simultaneous anterior- and posterior-circulation infarction.\n\n     A tandem lesion consisting of cervical internal carotid artery occlusion together with an intracranial large-vessel occlusion in the same vascular territory will not be automatically excluded if the treating neurointerventionalist considers endovascular therapy appropriate.\n  6. Confirmed moyamoya disease or moyamoya syndrome.\n  7. Substantial cerebral edema, mass effect, or midline shift on baseline computed tomography or magnetic resonance imaging.\n  8. Intracranial neoplasm that may affect the 90-day functional outcome, increase the risk of hemorrhage, or interfere with study assessment. A small, asymptomatic meningioma may be permitted at the investigator's discretion.","ALL","18 Years",{"count":19,"type":20},314,"ESTIMATED","INTERVENTIONAL",[23],"PHASE3","Although endovascular therapy (EVT) has substantially improved recanalization rates and extended the treatment window for acute ischemic stroke, fewer than half of patients achieve functional independence despite successful reperfusion. Growth of the ischemic core before reperfusion and ischemia-reperfusion injury after recanalization may contribute to unfavorable outcomes. Therefore, an adjunctive neuroprotective strategy that preserves the ischemic penumbra before and during EVT may further improve clinical outcomes.\n\nNormobaric hyperoxia (NBO) is a noninvasive and readily available treatment that delivers high-concentration oxygen at normal atmospheric pressure. By increasing oxygen delivery to hypoperfused but potentially salvageable brain tissue, NBO may delay infarct growth, preserve the blood-brain barrier, and reduce reperfusion injury. Previous preclinical studies and early clinical trials have suggested that NBO may provide neuroprotection without increasing oxidative stress or other major safety risks. The previous OPENS-1 and OPENS-2 trials showed that periprocedural NBO combined with EVT reduced infarct volume and improved 90-day functional outcomes in patients treated within 6 hours after stroke onset. In addition, a preliminary two-center study involving 120 patients treated 6-24 hours after onset suggested greater early neurological improvement and a potentially favorable 90-day functional outcome with NBO plus EVT compared with EVT alone.\n\nOPENS-EXTEND is a prospective, multicenter, randomized controlled trial designed to evaluate the efficacy and safety of periprocedural NBO as an adjunct to EVT in patients with acute ischemic stroke caused by anterior-circulation large-vessel occlusion who present 6-24 hours after symptom onset or last known well and have imaging evidence of salvageable ischemic brain tissue. Participants will be randomly assigned to receive either EVT combined with NBO or EVT with standard medical management alone. The primary hypothesis is that adjunctive NBO will improve functional outcomes at 90 days without increasing safety risks.",[26,27,28,29],"Stroke, Acute","Neuroprotection","Normobaric Hyperoxia","Endovascular Treatment","NOT_YET_RECRUITING","2026-07-17",{"date":33,"type":34},"2026-07-21","ACTUAL",{"date":36,"type":20},"2026-09-01",{"date":38,"type":20},"2029-09-01",{"name":40,"class":41},"Weifang Medical University","OTHER",{"id":43,"slug":44,"hasResults":11,"nctId":45,"briefTitle":46,"officialTitle":47,"acronym":48,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":50,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":21,"phases":54,"briefSummary":56,"conditions":57,"keywords":60,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":80},"100617772","evaluation-of-brudyglauco-dha--citicoline-in-patients-with-glaucoma-100617772","NCT07322965","Evaluation of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma","Evaluation of the Effect of BRUDYGLAUCO (DHA + Citicoline) in Patients With Glaucoma","BRUDYGLAUCO","Inclusion Criteria:\n\n1. Patients with chronic glaucoma (primary or secondary, open-angle or closed-angle) diagnosed in at least one eye, meeting the following criteria:\n\n   Structural damage: Thinning of the neuroretinal rim, peripapillary hemorrhage, or reduction in the nerve fiber layer, confirmed by OCT or color fundus photography.\n\n   Functional damage: At least 3 contiguous abnormal points outside the 95% confidence limit in the pattern deviation map of the visual field.\n2. At least 4 reliable visual field (VF) tests before study enrollment.\n3. Age between 50 and 75 years.\n4. If both eyes meet the inclusion criteria, the eye with the worst Mean Deviation (MD) will be selected as the study eye.\n\nExclusion Criteria:\n\n1. Use of any vitamin or nutraceutical supplement in the month prior to screening.\n2. Any condition that could alter visual field testing, including:\n\n   Neurological diseases. Retinal diseases. Advanced cataracts. Treatment with Lyrica (Pregabalin) due to its effect on visual fields.\n3. Hypersensitivity to acetylsalicylic acid (aspirin) (cross-reactivity risk with citicoline).\n4. Ocular surgery or laser treatment in the 3 months prior to enrollment or planned during the study.\n5. Mean Deviation (MD) of the visual field worse than -20 dB or better than -3 dB.","50 Years","75 Years",{"count":53,"type":20},108,[55],"NA","This study aims to evaluate the effects of BrudyGlauco, a nutritional supplement containing DHA (docosahexaenoic acid) and citicoline, on visual function in people with glaucoma. Glaucoma is a progressive optic neuropathy that can lead to vision loss. Current treatments focus on lowering eye pressure, but there are other pathogenic factors and the use of additional therapies that could protect or regenerate the optic nerve would be beneficial.\n\nThis is a randomized, double-blind, placebo-controlled, and multicenter clinical trial. Participants will be randomly assigned to receive either BrudyGlauco or a placebo for 12 months. The study will assess changes in visual field, safety, and treatment adherence.\n\nThe trial is being conducted at the Institut Català de Retina (ICR) and Hospital de la Esperanza. Participants will undergo regular eye exams, visual field tests, and follow-ups to monitor potential improvements in visual function.\n\nThe results of this study will help determine if BrudyGlauco can provide neuroprotective benefits for people with glaucoma and improve their quality of life.",[58,59,27],"Glaucoma","Primary Open Angle Glaucoma (POAG)",[61,62,27,63,64,65,66,67,68,69],"glaucoma","Primary Open-Angle Glaucoma (POAG)","Visual Field","DHA (Docosahexaenoic Acid)","Citicoline","Nutritional Supplement","Clinical Trial","Randomized Controlled Trial (RCT)","Visual Function","RECRUITING","2026-01-12",{"date":73,"type":34},"2026-01-14",{"date":75,"type":34},"2025-04-01",{"date":77,"type":20},"2027-05-30",{"name":79,"class":41},"Institut Catala de Retina",2,{"id":82,"slug":83,"hasResults":11,"nctId":84,"briefTitle":85,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":21,"phases":90,"briefSummary":91,"conditions":92,"keywords":4,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":94,"lastUpdatePostDateStruct":95,"startDateStruct":97,"completionDateStruct":99,"leadSponsor":101,"locationsCount":103},"100413542","intra-arterial-neuroprotective-strategy-for-ischemic-stroke-patients-with-no-reperfusion-therapy-insist-nrt-100413542","NCT04664946","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT)","Intra-arterial Neuroprotective Strategy for Ischemic STroke Patients With No Reperfusion Therapy (INSIST-NRT): One Single Center, Safety and Feasibility Study","Inclusion Criteria:\n\n1. Age ≥18 years;\n2. Major neurologic deficits: 6≤NIHSS≤20;\n3. Missing recanalization therapy (IVT or EVT) or progressive stroke, which was defined as symptoms worsen in 48 hours (an increase in NIHSS more than 4);\n4. Premorbid mRS 0 or 1;\n5. Signed informed consent.\n\nExclusion Criteria:\n\n1. Modified Rankin Score \\>2 caused by a history of prior stroke;\n2. Patients who underwent intravenous thrombolysis or Endovascular treatment;\n3. Coagulation disorders, systematic hemorrhagic tendency, thrombocytopenia （ \\\u003C80000\u002Fmm3;\n4. Severe hepatic or renal dysfunction, increase in ALT or AST (more than 2 times of upper limit of normal value), increase in serum creatinine (more than 1.5 times of upper limit of normal value) or requiring dialysis;\n5. Severe hypertension (systolic blood pressure over 200mmHg or diastolic blood pressure over 110 mmHg);\n6. Unsuitable for this clinical studies assessed by researcher.",{"count":89,"type":20},30,[55],"To explore the safety and feasibility of intra-arterial neuroprotective strategy in acute ischemic stroke patients who missed recanalization operation.",[93,27],"Ischemic Stroke","2025-08-20",{"date":96,"type":34},"2025-08-21",{"date":98,"type":34},"2020-12-01",{"date":100,"type":20},"2026-05-01",{"name":102,"class":41},"Hui-Sheng Chen",1,{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":108,"acronym":109,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":111,"enrollmentInfo":112,"targetDuration":4,"studyType":21,"phases":114,"briefSummary":115,"conditions":116,"keywords":118,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":130,"lastUpdatePostDateStruct":131,"startDateStruct":133,"completionDateStruct":135,"leadSponsor":137,"locationsCount":5},"100379195","phase-3-cerebrum-and-cardiac-protection-with-allopurinol-in-neonates-with-critical-congenital-heart-disease-requiring-cardiac-surgery-with-cardiopulmonary-bypass-100379195","NCT04217421","Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass","CRUCIAL","Inclusion Criteria:\n\n* Neonates with a prenatally or postnatally confirmed diagnosis of CCHD requiring (anticipated) cardiac surgery with CPB within the first 4 weeks of life.\n* Informed consent provided by both parents.\n\nExclusion Criteria:\n\n* Inability to enroll the patient before the start of delivery in case of prenatal diagnosis, or 24 hours before surgery in case of postnatal diagnosis.\n* Doubt whether the aortic arch anomaly before birth requires cardiac surgery with CPB in the neonatal period.\n* Gestational age below 36 weeks and\u002For birth weight less than 2000 gram.\n* Surgery not requiring cardiopulmonary bypass.\n* Decision for \"comfort care only\".","1 Month",{"count":113,"type":20},236,[23],"Neurodevelopmental impairment due to delayed brain development and brain injury is a fundamental problem in children with critical congenital heart disease (CCHD). Significant longterm motor-, cognitive-, and behavioral problems are the result of early postnatally and perioperatively induced brain injury. Allopurinol, a xanthine oxidase inhibitor, prevents the formation of toxic free oxygen radicals, thereby limiting hypoxia-reperfusion damage. Both animal and neonatal studies suggest that administration of allopurinol reduces hypoxic-ischemic brain injury, is cardioprotective, and safe. This study aims to evaluate the efficacy and safety of allopurinol administered early postnatally and perioperatively in children with a CCHD requiring cardiac surgery with cardiopulmonary bypass.",[117,27],"Congenital Heart Disease in Children",[119,27,120,121,122,123,124,125,126,127,128,129],"Congenital Heart Disease","Allopurinol","Brain injury","Cardiopulmonary bypass","Brain function","Brain oxygenation","Cardiac function","Neurodevelopmental outcome","Cardiac surgery","Hypoxic-ischemic brain injury","Neonates","2024-05-13",{"date":132,"type":34},"2024-05-16",{"date":134,"type":34},"2020-02-14",{"date":136,"type":20},"2028-12-31",{"name":138,"class":41},"dr. M.J.N.L. Benders"]